Beijing GoBroad Healthcare Group Hospitals

GoBroad Healthcare Group Hospitals (GHG) is a pioneer of the research-oriented hospital mode in China specialized on Hematology and Oncology, we currently operates 8 hospitals in Beijing, Shanghai and Guangzhou, with a combined open bed capacity of nearly 1500 beds, and mainly focuses on clinical treatment, clinical research, reference laboratories and information technology. GHG has joined hands with a group of top-notch medical experts with rich clinical experience and scientific research backgrounds to create a unique “Academic Research Organization (ARO)”. Our organizational strategy is to build an innovative medical ecosystem of “clinical discovery-basic research-industrial transformation-clinical application” and improve the efficiency and quality of development in the biomedicine industry. We have always adhered to the value of “The Needs of the Patient Come First” and is committed to building a clinical-oriented, innovative medical technology platform. With the mission and vision of pursuing excellence in the diagnosis and treatment of diseases, employing technological innovation and pursuing the hope of diseases, we are progressively building our hospital group into several leading hematology and cancer research hospitals. A research-oriented hospital is an important carrier of the ARO mode, the GHG focuses on innovative and research-active specialties such as solid tumors, hematological diseases and brain science. GHG has established professional service fields, including a Phase I clinical trial ward, a central laboratory, and an early-stage clinical research center, while providing clinical pharmacology, medicine, and statistical analysis. We are a national leader in a number of cancer therapies, such as adoptive cell therapy, immunotherapy and targeted therapy. In particular, our team of experts has extensive experience in chimeric antigen receptor T cell immunotherapy, also known as CAR-T Therapy, they have published over 70 academic papers globally and delivered more than 100 presentations at international conferences such as ASH, EHA, and ASCO. To date, we have successfully treated nearly 5,000 patients using CAR-T cell therapy, helped over 1000 patients from overseas, making us the most experienced CAR-T treatment center in China. In addition, we are equipped with a professional healthcare multidisciplinary team to provide comprehensive and personalized integrated medical care in pursuit of more accurate diagnosis and more humanistic patient services.  With the medical mission of treating severe diseases that have proved to be difficult to treat, GHG has brought more treatment options and hope to the vast number of patients with severe diseases that are difficult to treat. With the scientific research mission of promoting medical innovation, GHG has served hundreds of innovative pharmaceutical companies in a large number of innovative drug clinical trials. Advances in medicine are stemmed from the idea that encourages innovation, and improvements in innovation are derived from the practice of embracing medicine.

Beijing, Shanghai, Guangzhou - Beijing, Shanghai, Guangzhou - China

Short info:

Send Request


About Gobroad Healthcare Group

GoBroad Healthcare Group Hospitals (GHG) is a pioneer of the research-oriented hospital mode in China specialized on Hematology and Oncology, we currently operates 8 hospitals in Beijing, Shanghai and Guangzhou, with a combined open bed capacity of nearly 1500 beds, and mainly focuses on clinical treatment, clinical research, reference laboratories and information technology. GHG has joined hands with a group of top-notch medical experts with rich clinical experience and scientific research backgrounds to create a unique “Academic Research Organization (ARO)”. Our organizational strategy is to build an innovative medical ecosystem of “clinical discovery-basic research-industrial transformation-clinical application” and improve the efficiency and quality of development in the biomedicine industry.

We have always adhered to the value of “The Needs of the Patient Come First” and is committed to building a clinical-oriented, innovative medical technology platform. With the mission and vision of pursuing excellence in the diagnosis and treatment of diseases, employing technological innovation and pursuing the hope of diseases, we are progressively building our hospital group into several leading hematology and cancer research hospitals.

A research-oriented hospital is an important carrier of the ARO mode, the GHG focuses on innovative and research-active specialties such as solid tumors, hematological diseases and brain science. GHG has established professional service fields, including a Phase I clinical trial ward, a central laboratory, and an early-stage clinical research center, while providing clinical pharmacology, medicine, and statistical analysis. We are a national leader in a number of cancer therapies, such as adoptive cell therapy, immunotherapy and targeted therapy. In particular, our team of experts has extensive experience in chimeric antigen receptor T cell immunotherapy, also known as CAR-T Therapy, they have published over 70 academic papers globally and delivered more than 100 presentations at international conferences such as ASH, EHA, and ASCO. To date, we have successfully treated nearly 5,000 patients using CAR-T cell therapy, helped over 1000 patients from overseas, making us the most experienced CAR-T treatment center in China. In addition, we are equipped with a professional healthcare multidisciplinary team to provide comprehensive and personalized integrated medical care in pursuit of more accurate diagnosis and more humanistic patient services. 

With the medical mission of treating severe diseases that have proved to be difficult to treat, GHG has brought more treatment options and hope to the vast number of patients with severe diseases that are difficult to treat. With the scientific research mission of promoting medical innovation, GHG has served hundreds of innovative pharmaceutical companies in a large number of innovative drug clinical trials. Advances in medicine are stemmed from the idea that encourages innovation, and improvements in innovation are derived from the practice of embracing medicine.

Hospitals of Gobroad Healthcare Group

Gobroad Healthcare Group has a network of 7 hospitals that are strategically located in the main cities of China.

Beijing Gobroad Hospital

Beijing Gobroad Hospital is a pioneering research hospital where severe cases are diagnosed and treated. The hospital has a construction area of about 100,000 square meters and a capacity of 500 beds, including 100 early-stage research beds.

Beijing Gobroad Boren Hospital

Beijing Gobroad Boren Hospital is a secondary general hospital and flagship facility of GHG. The hospital offers specialized services for blood tumors, Parkinson's disease, and liver cancer, along with comprehensive inpatient and emergency care.

It has 170 beds, including 19 Class 100 laminar flow wards, and advanced diagnostic and treatment rooms. In addition, the hospital supports cutting-edge clinical research and drug trials.

Shanghai Gobroad Cancer Hospital

Shanghai Gobroad Cancer Hospital, affiliated with China Pharmaceutical University, is a leading tertiary cancer research hospital of the group. It is located in the Pudong New District and has a total construction area of 70,000 square meters.

Phase I has 406 beds, and Phase II is under development to add approximately 700 beds. The hospital is an important part of Gobroad's innovative medical technology platform.

Gobroad Medical (Hematology) Shanghai Research Center

The Gobroad Medical (Hematology) Shanghai Research Center, including Shanghai Zhaxin Hospital and Shanghai Liquan Hospital, is renowned for its expertise in hematology.

As part of the Shanghai Ruijin Hospital Hematology Medical Consortium, these hospitals offer over 300 beds and 32 laminar flow wards for hematopoietic stem cell transplantation.

They are equipped with advanced diagnostic and treatment facilities, including gene testing and PCR, and specialize in complex hematological conditions and innovative therapies. The center's team, led by Professor Wang Chun, is noted for treatment of leukemia and advanced stem cell transplantation techniques.

Nanfang-Chunfu Children's Institute of Hematology

The Southern Chunfu (Children) Hematology Research Institute focuses on pediatric hematology and has a partnership with Mayo Clinic. It has 150 beds and 36 hematopoietic stem cell transplantation chambers.

The institute has performed 1,223 hematopoietic stem cell transplants and is recognized for its research and high survival rates.

Another hospital, Guangdong GoBroad, is under construction in Guangzhou.

Infrastructure

The hospitals of the group have state-of-the-art infrastructure that supports cutting-edge medical research and treatment of cancer.

  • 1500 hospital beds
  • 2 reference laboratories
  • 1 central laboratory
  • 100 clean rooms for Hematopoietic Stem Cell Transplantation
  • Specialized Centers
  • Phase I clinical trial wards
    • Early clinical research centers
    • Clinical pharmacology units
    • Central laboratories
    • Medical centers for difficult diseases
    • Medical centers for international patients
  • Innovative Center for Translational Medicine

Why Choose Gobroad Healthcare Group?

Gobroad is known for its innovative treatment approach towards difficult and complex cancers. Patients from all over the world choose the hospital for the following reasons:

Experienced Doctors

The hospitals and research centers of the Gobroad Group have around 2000 doctors who are extremely skilled and have extensive experiences.

Most of them have received international training and have around 20 to 30 years of experience. They also regularly participate in clinical trials and are pioneers of new cancer diagnosis and treatment techniques.

For example, Dr. Yonghong ZHANG pioneered the use of sequential infusion therapy with CD19/CD20/CD22 CAR-T cells. Similarly, Dr. Chun WANG pioneered the monitoring technology for transplant chimerism. He also performed 500 stem cell transplants along with his team.

Advance Technology

Gobroad hospitals are internationally renowned for being equipped with the most latest technology used in cancer treatment. Some of the advanced technologies available include:

  • State-of-the-art imaging systems, including the latest MRI, CT, and PET scanners (e.g., 3T MRI, PET/CT scanners)
  • Cutting-edge linear accelerators and proton therapy systems for radiotherapy (e.g., Varian TrueBeam, Proton Therapy)
  • Robotic-assisted systems for minimally invasive surgeries
  • Advanced genetic testing and molecular profiling (e.g., Next-Generation Sequencing, Liquid Biopsy)
  • Immunotherapy techniques (e.g., CAR T-cell therapy, Checkpoint Inhibitors)

Innovative Clinical Trials and Research

Gobroad Healthcare Group is dedicated to advancing medical research and providing innovative treatments through various clinical trials. Over 470 trials are ongoing in various phases at the research centers.

Other significant research contributions of the group include:

  • Presentation of 14 research findings at EHA2024 & ASCO2024, focusing on unmet patient needs.
  • Delivery of 6 research results at EBMT2024, showing continuous innovation.
  • Presentation of 15 research results at ASH2023, displaying expertise in hematology.

Moreover, most of the research of Gobroad Medical Group is published in international scientific journals like the Lancet, Journal of Clinical Oncology, and Journal of Hematology and Oncology.

International Recognition and Participation

Gobroad Healthcare Group is internationally recognized for its contributions to innovative and new cancer treatments. Some of the notable achievements of the group include:

  • Doctors of the group presented research findings at prestigious international conferences such as EHA2024, ASCO2024, EBMT2024, and ASH2023.
  • Gobroad also participated in the 2024 DIA conference, supporting advancements in China's ADC/RDC research and development.

Personalized and Compassionate Care

Gobroad Hospitals provides personalized and compassionate care to every patient by offering treatment plans tailored to individual needs.

This treatment plan includes accurate diagnosis and treatment procedures, including chemotherapy, radiotherapy, and immunotherapy, followed by comprehensive aftercare services.

Services for International Patients at Gobroad Healthcare Group

GHG offers a range of services for international patients. The network's International Patient Service Center plays a key role in this by offering comprehensive support throughout your medical journey.

Upon contacting the International Patient Service Center, patients will be assigned a dedicated coordinator who will assist them throughout. Their services include:

  • Scheduling online or offline consultations and assistance with follow-up on your appointments
  • Assistance in visa procedures
  • Outpatient and Hospitalization Support
  • Assistance with financial issues, insurance policies, and handling medical billing
  • Arranging food and accommodation
  • Managing discharge procedures
  • Assistance with follow-up appointments